Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Will Be Watching Discussions on Eligibility Criteria for Companies to Receive Price Maintenance Premium
May 29, 2017
- Suzuki to Serve His 3rd Term as JPWA Chief
May 26, 2017
- Japan Microbiome Consortium Inaugurated by Drug Makers to Promote Drug Discovery Research
May 25, 2017
- Price Band Rule Raising Prices of Rock-Bottom Generics: Sawai President
May 24, 2017
- Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
May 17, 2017
- Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA
May 15, 2017
- JGA’s 1st Industry Vision Envisages Consolidation into 4 Biz Models
May 8, 2017
- JPMA to Draw Up Proposals on Continuous Manufacturing: Quality & Technology Committee
April 27, 2017
- JPMA to Focus on New Developments Including GCP Reform in FY2017: Drug Evaluation Committee
April 27, 2017
- Broader Approach to HTA Could Be Used to Validate Initial Pricing Premiums: PhRMA HTA Chief
April 26, 2017
- JPMA to Focus on Initiative to Reflect Post-Marketing Evidence for Efficacy in Package Inserts
April 26, 2017
- JPMA Says Bayer Rep Contacted It Last July over Xarelto Survey, Issue Should Be First Handled by Regulators
April 24, 2017
- PhRMA Submits Paper to Lawmaker Group, Demands Price Maintenance for On-Patent Drugs
April 21, 2017
- Innovation Premium Top Priority for 3 Trade Groups; EFPIA Ideally Wants Its Expansion
April 20, 2017
- Masaru Nakamura Resigns as Chairman of NPhA in Wake of False Claim Scandal Involving Qol
April 18, 2017
- PhRMA Chair Repeats Call for Keeping Price Maintenance Premium to Secure Market Predictability
April 13, 2017
- JGA Fires Back at Criticism on “Excessive” and “Expensive” Generics, Says No. of Makers Not So Many
April 11, 2017
- Asian Industry Groups Promote Collaboration to Discover Drugs from Natural Resources by Leveraging Asia’s Diverse Ecosystems
April 10, 2017
- JPMA to Support Japanese Drug Makers’ Overseas Expansion through Public-Private Cooperation
April 10, 2017
- Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
April 7, 2017
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…